{"id":894,"date":"2020-02-18T11:08:13","date_gmt":"2020-02-18T05:38:13","guid":{"rendered":"https:\/\/medicineplexus.com\/?p=894"},"modified":"2020-02-18T11:08:13","modified_gmt":"2020-02-18T05:38:13","slug":"nano-pharmacology","status":"publish","type":"post","link":"https:\/\/medicineplexus.com\/nano-pharmacology\/","title":{"rendered":"Nano-pharmacology"},"content":{"rendered":"\n
Nano-pharmacology<\/strong><\/p>\n\n\n\n Nanotechnology is continuously being explored in the field of medicine with the objective of maximizing current therapeutic strategies and minimizing side effects of drugs. Nano-pharmacology is concerned with the application of nanotechnology on the basis of novel pharmacological principles with a view to increase therapeutic ef\ufb01cacy and reduce side effects, and to achieve targeted delivery of medicine to speci\ufb01c sites in a controlled manner.(1)<\/p>\n\n\n\n Integration of nanotechnology with pharmacology for enhanced chemotherapy in multidrug-resistant cancer:<\/strong>Multidrug resistance (MDR) in cancer is a common clinical problem. It involves complex cellular and non-cellular mechanisms (e.g. the aberrant tumour micro-environment i.e. TME), which can collectively contribute to reduced drug concentrations, activities and efficacy at tumour sites and within cancer cells, leading to ineffective chemotherapy.(2) To overcome the multifactorial MDR mechanisms for improved chemotherapy, various approaches have been investigated, such as the development of new anticancer drugs that are poor substrates for efflux transporters, downregulation of MDR-associated enzymes using RNA interference; synergistic drug combination with different mechanisms of drug actions and multifunctional nanoparticles (NPs). Solid polymer-lipid hybrid NPs<\/strong> (PLNs) have been designed to bypass efflux transporters and synergistic drug combinations or drug-nanomaterial combinations in NPs have been explored.(3) Once administered intravenously into the body, the drug combination non-specifically distributes to normal organs before reaching the tumour due to the different pharmacokinetic profiles of each drug, resulting in increased adverse effects. Application of nanotechnology in drug delivery makes it possible to deliver synergistic drug combinations ratiometrically and spatial-temporally to the sites of drug action(4). The use of nanosized drug carriers, several nanoparticle formulations of synergistic drug combination have been moved to clinical trials(5) or have gained approval by the United States Food and Drug Administration (US-FDA) or other regulatory agencies(6).<\/p>\n\n\n\n Harnessing intracellular drug-drug interactions to design synergistic nanomedicine: <\/strong>It is known that under the hypoxic conditions of the TME, the cytotoxicity of Doxorubicin (DOX) is attenuated, as its activity partially relies on the presence of oxygen to generate free radicals that can cause DNA damage.\u00a0 In contrast, mitomycin-c (MMC) can be activated under hypoxia through a sequential one electron reduction pathway that enhances its cytotoxicity and can generate free radicals in the presence of oxygen(7).\u00a0 In addition, DOX and MMC damage DNA by different mechanisms: DOX causes DNA double-strand breaks by poisoning topoisomerase II\u03b1 an enzyme responsible for catalyzing the unwinding of DNA for transcription and replication, whereas MMC induces DNA intra-strand and inter-strand crosslinks to disrupt cell maintenance and replication(8).\u00a0 However, the clinical combination of DOX and MMC (DOX-MMC) was halted owing to its severe cardiotoxicity to cancer patients. This off-target adverse effect could be reduced with optimal scheduling and dosing of the two drugs by rationally designing a drug nanocarrier system(9). PLN formulation coloaded with DOX- MMC<\/strong> (DMPLN) designed with a key capability of synchronizing co-delivery of locally bioavailable DOX-MMC combination at synergistic ratios to cancer cells.\u00a0 As a result, DMPLN provided superior advantages over free DOX-MMC solution and liposomal DOX with enhanced tumour cell apoptosis and minimum cardiotoxicity, as well as prolonged host-survival in both human and murine MDR tumour models(10).<\/p>\n\n\n\n Harnessing naturally occurring lipoprotein to design self-decorating nanoparticles for drug delivery to the brain: <\/strong>Nearly 15%\u201330% of patients with advanced breast cancer develop brain metastases during progression of the disease. Brain metastases are associated not only with a poor prognosis but also with severe neurological impairment. The treatment of brain metastases is challenging due to the inability of most therapeutic agents to penetrate the BBB, leading to subtherapeutic drug accumulation in the CNS. The drug efflux transporters found on brain endothelial cell membranes of BBB further expel substrate molecules, including many effective anticancer drugs from the brain. As a result, it restricts passive entry of nearly 98% of all drugs to the brain at the blood-brain interface(11). Therefore, development of effective strategies for shuttling drugs across the BBB has been a long-standing goal in the drug delivery field. Of the various receptor-mediated brain-penetrating systems, NPs present more advantages than antibody-drug conjugates. Nanoparticle carriers can be engineered by surface decoration of targeting antibodies or ligands via covalent bonds or physical coating. Compared to pre-engineered nanocarrier systems, NPs that are able to adsorb receptor-binding moieties from the blood during circulation are more attractive owing to their low immunogenicity and cost effectiveness. Delivery of a therapeutic antibody to the brain requires particular considerations differing from the delivery of small molecules. To deliver therapeutic antibody TRA to human epidermal growth factor receptor-2 (HER2)-positive cancer cells in the brain metastasis area, an intracellularly eroded solid-lipid polymer matrix containing a TRA-conjugated terpolymer can be used. The nanoconstructs were able to shield TRA in the circulatory system and deliver it to brain tumours via a two-step targeting process. The constructs remained intact during systemic circulation, crossed the BBB (i.e. the first step in targeting the brain), and then n dissociated and exposed TRA, enabling the second-step targeting of TRA to the cancer cells within the brain and thus generating a therapeutic effect(12).<\/p>\n\n\n\n Integration of nanotechnology with pathophysiological features for disease-responsive drug delivery and enhanced radiation therapy: <\/strong>Various nanotechnology-based strategies have been developed to modulate TME<\/strong>, including 1) Nanoparticle formulations of angiogenesis inhibitors or small interfering RNA (siRNA) against vascular endothelial growth factor receptor-2 (VEGFR-2) to remodel the tumour vasculature, 2) Compounds for reducing\/degrading collagen content in the tumour extracellular matrix, and 3) Cytokines to modulate the phenotype of tumour-associated macrophages (TAMs)(13). Preclinical studies using orthotopic breast tumour models demonstrated good tumour accumulation and sustained effects of the lipid-polymer-based MDNPS (LMD NPs) on modulating TME factors(14).<\/p>\n\n\n\n Mimicking dynamic insulin release from human pancreatic cells: <\/strong>In healthy individuals, insulin secretion by pancreatic \u03b2-cells is synchronized with glucose level via a quick pulsatile surge when the glucose level rises after a meal and brings it down to euglycemia within 30\u201360 min.(15) In type 1 diabetes patients mimicking this dynamic insulin release pattern is critical to avoid extended tissue exposure to hyperglycemia and the risk of hypoglycemia. However, even with frequent self-monitoring of glucose level and administration of anticipated amounts of insulin, conventional insulin therapy is far from the ideal physiological response. Therefore, closed-loop insulin delivery systems have been developed to automate these steps with the use of continuous blood glucose monitors and insulin pumps to better emulate physiological conditions and minimize user\u2019s intervention. However, issues regarding the cost of the pumps and accessories and the short usage duration (3\u20137 d) of the accessories remain to be resolved(16). Recent advances in nanomaterials offer new opportunities for developing next-generation closed-loop insulin delivery systems<\/strong> that better mimic the endocrinological secretion of insulin. Our laboratory introduced pH-responsive hydrogel NPs to replicate the rapid and dynamic insulin release at physiologically relevant time scales. After implantation of hydrogel NPs in T1D rats, this nanotechnology-enabled insulin delivery system was able to reproducibly bring elevated blood glucose levels down to normal levels within 30 min after induced hyperglycemia, which mimics the endogenous insulin response time of healthy rats and resembles the pattern in healthy humans(17).<\/p>\n\n\n\n Current status of the nanopharmacology based medicines: (18)<\/u><\/strong><\/p>\n\n\n\n